TRAILR2/TNFRSF10B Antibody (tigatuzumab) [Janelia Fluor® 646]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28342JF646
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Janelia Fluor 646
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # tigatuzumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
TNFRSF10B / TRAILR2 / CD262
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for TRAILR2/TNFRSF10B Antibody (tigatuzumab) [Janelia Fluor® 646]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: TRAIL R2/TNFRSF10B
Long Name
TRAIL Receptor 2
Alternate Names
CD262, DR5, TNFRSF10B, TRAILR2
Gene Symbol
TNFRSF10B
Additional TRAIL R2/TNFRSF10B Products
Product Documents for TRAILR2/TNFRSF10B Antibody (tigatuzumab) [Janelia Fluor® 646]
Product Specific Notices for TRAILR2/TNFRSF10B Antibody (tigatuzumab) [Janelia Fluor® 646]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...